Skip to content

Catalyst Pharmaceutical CPRX Other Commercial Liabilities

Other Commercial Liabilities at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Scholar Rock logo
Scholar RockSRRK
Arrowhead Research logo
Arrowhead ResearchARWR
ALN
Alnylam PharmaceuticalsALNY
Cytokinetics logo
CytokineticsCYTK

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's other commercial liabilities?
Catalyst Pharmaceutical (CPRX) reported other commercial liabilities of $125.25M in Q1 2026.
How has Catalyst Pharmaceutical's other commercial liabilities changed year-over-year?
Catalyst Pharmaceutical's other commercial liabilities increased by 24.7% year-over-year, from $100.45M to $125.25M.
What is the long-term trend for Catalyst Pharmaceutical's other commercial liabilities?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's other commercial liabilities has grown at a 49.0% compound annual growth rate (CAGR), from $18.5M to $135.95M.